

Title (en)  
IMMUNE POTENTIATING COMPOSITIONS

Title (de)  
IMMUNSYSTEM STEIGERENDE ZUSAMMENSETZUNGEN

Title (fr)  
COMPOSITIONS POTENTIALISATRICES IMMUNES

Publication  
**EP 1313839 B1 20140319 (EN)**

Application  
**EP 01931205 A 20010517**

Priority  
• AU 0100565 W 20010517  
• AU PQ755300 A 20000517

Abstract (en)  
[origin: WO0188097A1] A composition of matter is disclosed, comprising an immunostimulatory molecule and animal cells cultured in the presence of at least one interferon (IFN) for a time and under conditions sufficient to enhance the antigen presenting function of said cells. Also disclosed are immunopotentiating compositions and their use for treatment and/or prophylaxis of a disease or condition.

IPC 8 full level  
**C12N 5/07** (2010.01); **C12N 15/09** (2006.01); **A61K 39/00** (2006.01); **A61K 39/002** (2006.01); **A61K 39/02** (2006.01); **A61K 39/12** (2006.01); **A61K 39/39** (2006.01); **A61K 39/395** (2006.01); **A61K 45/00** (2006.01); **A61P 31/00** (2006.01); **A61P 31/04** (2006.01); **A61P 31/10** (2006.01); **A61P 31/12** (2006.01); **A61P 35/00** (2006.01); **C12N 5/09** (2010.01); **C12N 5/10** (2006.01); **C12Q 1/02** (2006.01); **C12Q 1/68** (2006.01); **A61K 35/12** (2006.01)

CPC (source: EP US)  
**A61K 39/0011** (2013.01 - EP US); **A61K 39/4611** (2023.05 - EP); **A61K 39/464411** (2023.05 - EP); **A61P 31/00** (2018.01 - EP); **A61P 31/04** (2018.01 - EP); **A61P 31/10** (2018.01 - EP); **A61P 31/12** (2018.01 - EP); **A61P 35/00** (2018.01 - EP); **A61P 37/02** (2018.01 - EP); **A61P 37/04** (2018.01 - EP); **C12N 5/0693** (2013.01 - EP US); **A61K 35/12** (2013.01 - EP US); **C12N 2501/24** (2013.01 - EP US); **C12N 2501/51** (2013.01 - EP US); **C12N 2501/58** (2013.01 - EP US)

Citation (examination)  
• DENFELD RALF W ET AL: "In situ expression of B7 and CD28 receptor families in human malignant melanoma: Relevance for T-cell-mediated anti-tumor immunity", INTERNATIONAL JOURNAL OF CANCER, vol. 62, no. 3, 1995, pages 259 - 265, ISSN: 0020-7136  
• MORANDINI R ET AL: "Modulation of ICAM-1 expression by alpha-MSH in human melanoma cells and melanocytes", JOURNAL OF CELLULAR PHYSIOLOGY, vol. 175, no. 3, June 1998 (1998-06-01), pages 276 - 282, ISSN: 0021-9541  
• STURMHOFEL K ET AL: "POTENT ACTIVITY OF SOLUBLE B7-IGG FUSION PROTEINS IN THERAPY OF ESTABLISHED TUMORS AND AS VACCINE ADJUVANT", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 59, no. 19, 1 October 1999 (1999-10-01), pages 4964 - 4972, XP000941780, ISSN: 0008-5472  
• MORO MONICA ET AL: "Induction of therapeutic T-cell immunity by tumor targeting with soluble recombinant B7-immunoglobulin costimulatory molecules", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 59, no. 11, 1 June 1999 (1999-06-01), pages 2650 - 2656, XP002154490, ISSN: 0008-5472

Designated contracting state (EPC)  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

DOCDB simple family (publication)  
**WO 0188097 A1 20011122**; AU PQ755300 A0 20000608; CA 2408756 A1 20011122; CA 2408756 C 20141209; EP 1313839 A1 20030528; EP 1313839 A4 20060125; EP 1313839 B1 20140319; JP 2003533539 A 20031111; JP 4943621 B2 20120530; US 2004235156 A1 20041125; US 2009081792 A1 20090326; US 7455846 B2 20081125; US 7964400 B2 20110621

DOCDB simple family (application)  
**AU 0100565 W 20010517**; AU PQ755300 A 20000517; CA 2408756 A 20010517; EP 01931205 A 20010517; JP 2001585305 A 20010517; US 25919408 A 20081027; US 27664203 A 20030630